|
|
|
| Analysis of the best application time of Tirofiban on patients with acute ST segment elevation myocardial infarction undergoing PCI |
| ZHANG Nan |
| Department of Emergency, Beijing Shijingshan Hospital, Beijing 100043, China |
|
|
|
Abstract Objective To explore the effect of Tirofiban application at different time on the patients with acute ST segment elevation myocardial infarction (STEMI) in PCI. Methods From February 2013 to May 2016, in Department of Emergency, Beijing Shijingshan Hospital, 200 patients with acute STEMI and accepted PCI treatment were selected, according the application time of Tirofiban, they were divided into the group A (95 cases, given Tirofiban after entering the resuscitation room immediately), group B (56 cases, given Tirofiban application at the end of the emergency after coronary angiography,) control group (49 cases, without Tirofiban). The therapeutic effect and safety the three groups were evaluated and compared. Results There were no significant differences in the aspects of TIMI flow grade and myocardial perfusion grade among the three groups before the PCI (P > 0.05). After PCI, there were no significant differences in the aspect of TIMI flow grade among the three groups (P > 0.05), but group A, group B were better than control group in TIMI myocardial perfusion grade， the differences were statistically significant (P < 0.05), there was no significant difference between group A and group B (P > 0.05). Before PCI, CK-MB, cTNT in three groups were copmpared, the differences were not statistically significant (P > 0.05). After PCI, CK-MB, cTNT in group A, group B were lower than control group, the differences were statistically significant (P < 0.05). Before PCI, NT-proBNP and cardiac function in three groups were compared, the differences were not statistically significant (P > 0.05). After PIC, NT-proBNP, LVEDD and LVESD in group A, group B were lower than control group, LVEF was higher than control group, the differences were not statistically significant (P > 0.05). Three patients were followed up for 6 months, occurrence rate of hemorrhage and thrombocytopenia, MACE of three groups were compared, the differences were not statistically significant (P > 0.05). Conclusion Application of tirofiban in STEMI patients with emergency PCI treatment can effectively improve blood flow and myocardial perfusion, decrease myocardial damage, and the earlier application, the effect is more significant, the adverse reactions were tolerable, it is worthy of promotion.
|
|
|
|
|
|
[1] 王字航，杨蕾，董淑娟.急性ST段抬高型心肌梗死患者行急诊PCI时替罗非班的使用时机及安全性[J].山东医药，2012，52（9）：75-76.
[2] 何文凯,李明琰,邢晓雯,等.替罗非班不同给药方式对急性心肌梗死患者PCI预后的影响[J].实用医学杂志，2012，28（17）：2936-2939.
[3] 刘红彬，刘志红，籍振国，等.替罗非班应用时间对急性ST段抬高型心肌梗死患者PCI围术期临床疗效及短期预后的影响[J].山东医药，2012，52（45）：36-38.
[4] Chilton R. IC bolus only versus IV with infusion 2b/3a inhibitors during STEMIs having PCI [J]. Catheter Cardiovasc Interv，2012，79（1）：68-69.
[5] 胡雅光，张会久，张志，等.替罗非班对糖尿病合并ST段抬高型急性心肌梗死患者经皮冠状动脉介入术后B型脑钠肽水平及心功能的影响[J].中国老年学杂志，2013，33（11）：2499-2501.
[6] 中华医学会心血管病学分会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001，16（12）：710-725.
[7] 张大鹏，王乐丰，王红石， 等.替罗非班对非介入治疗急性非ST段抬高心肌梗死患者的疗效[J].中华内科杂志，2014，54（3）：193-197.
[8] Salarifar M，Mousavi M，Yousefpour N，et al. Effect of early treatment with tirofiban on initial TIMI Grade 3 flow of patients with ST elevation myocardial infarction [J]. Iran Red Crescent Med J，2014，16（1）：e9641.
[9] Balghith MA. High bolus tirofibanvs abciximab in acute STEMI patients undergoing primary PCI——the Tamip Study [J]. Heart Views，2012，13（3）：85-90.
[10] Hermanides RS，van Werkum JW，Ottervanger JP，et al. The effect of pre-hospital glycoprotein Ⅱb-Ⅲa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI [J]. Catheter Cardiovasc Interv，2012，79（6）：956-964.
[11] 任琳，王文广，王倩，等.半量替罗非班在老年急性心肌梗死急诊经皮冠状动脉介入治疗的疗效和安全性[J].中华老年心脑血管病杂志，2014（1）：32-35.
[12] 高海，段小春，李南.替罗非班对急性心肌梗死行直接冠状动脉介入治疗患者血浆B型脑钠肽及心功能的影响[J].中国全科医学，2012，15（6）：618-621.
[13] 唐亮，屈晨，张曼.双倍负荷剂量替罗非班在急性ST段抬高型心肌梗死 PCI 手术中的应用研究[J].实用药物与临床，2014，17（1）：41-44.
[14] 张奇，张瑞岩，胡健，等.急性ST段抬高心肌梗死患者急诊介入治疗单纯冠状动脉内注射替罗非班的疗效及安全性[J].中国介入心脏病学杂志，2014（8）：483-487.
[15] 高兵，李卫伟，万国桢，等.急诊PCI治疗中应用血栓抽吸联合冠脉内IRA给予替罗非班对急性心肌梗死无复流的影响[J].山东医药，2012，52（4）：96-98.
[16] 周勇，徐飞.早期应用替罗非班对急性ST段抬高型心肌梗死行PCI术患者心功能的影响及安全性研究[J].中国动脉硬化杂志，2015，23（9）：907-910.
[17] 潘庆丽，霍本良，王立旗，等.替罗非班在急性心肌梗死急诊PCI中的应用效果分析[J].中国循证心血管医学杂志，2017，9（5）：609-611.
[18] 秦黎明，左红，王阿莉，等.替罗非班在急性ST段抬高型心肌梗死急诊PCI术前、术中的应用[J].皖南医学院学报，2014（6）：511-515.
[19] 马震，阳海红，张雷雨.老年急性ST段抬高型心肌梗死急诊PCI术后不同途径应用替罗非班的疗效[J].中国老年学，2015，37（8）：2023-2025.
[20] 吴淼，陈漠水，邢波，等.急性ST段抬高心肌梗死患者行PCI应用替罗非班效果观察[J].中国热带医学，2012， 12（8）：981-983. |
|
|
|
